文献速递肿瘤 PET/CT

共临床FDG-PET影像组学特征预测三阴性乳腺癌新辅助化疗反应

Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-07-30

本研究利用三阴性乳腺癌(TNBC)患者来源异种移植瘤(PDX)模型优化稳健的FDG-PET影像组学特征,并在TNBC共临床研究中用机器学习算法预测新辅助化疗反应。

要点

  • PDX优化的RadSig在临床共研究中预测反应优于常规SUV指标。
  • Naïve Bayes-RadSig在临床前PDX试验中预测和评估反应表现最佳。

核心结论

  • 在共临床影像试验中优化了稳健的FDG-PET影像组学特征,用于预测和评估TNBC治疗反应。

研究设计与样本

  • 招募TNBC患者及亚型匹配的PDX进入共临床FDG-PET成像试验,从PDX和人分割肿瘤中提取131个影像特征。
  • 基于可重复性、交叉相关性和体积独立性识别稳健特征,并用ReliefF排序结合CART、Naïve Bayes和SVM机器学习算法筛选预测特征。

主要发现

  • 在临床前PDX试验中,NB-RadSig在预测和评估治疗反应方面表现最高。
  • 在临床研究中,SVM-RadSig和NB-RadSig预测和评估反应的表现几乎相同,且优于SUVmean、SUVmax和SULpeak。

临床怎么用

  • FDG-PET影像组学特征(RadSig)可用于TNBC新辅助化疗反应的预测和评估,表现优于常规SUV指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to exploit the heterogeneity afforded by patient-derived tumor xenografts (PDX) to first, optimize and identify robust radiomic features to predict response to therapy in subtype-matched triple negative breast cancer (TNBC) PDX, and second, to implement PDX-optimized image features in a TNBC co-clinical study to predict response to therapy using machine learning (ML) algorithms. METHODS: TNBC patients and subtype-matched PDX were recruited into a co-clinical FDG-PET imaging trial to predict response to therapy. One hundred thirty-one imaging features were extracted from PDX and human-segmented tumors. Robust image features were identified based on reproducibility, cross-correlation, and volume independence. A rank importance of predictors using ReliefF was used to identify predictive radiomic features in the preclinical PDX trial in conjunction with ML algorithms: classification and regression tree (CART), Naïve Bayes (NB), and support vector machines (SVM). The top four PDX-optimized image features, defined as radiomic signatures (RadSig), from each task were then used to predict or assess response to therapy. Performance of RadSig in predicting/assessing response was compared to SUVmean, SUVmax, and lean body mass-normalized SULpeak measures. RESULTS: Sixty-four out of 131 preclinical imaging features were identified as robust. NB-RadSig performed highest in predicting and assessing response to therapy in the preclinical PDX trial. In the clinical study, the performance of SVM-RadSig and NB-RadSig to predict and assess response was practically identical and superior to SUVmean, SUVmax, and SULpeak measures. CONCLUSIONS: We optimized robust FDG-PET radiomic signatures (RadSig) to predict and assess response to therapy in the context of a co-clinical imaging trial.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Roy S, Whitehead TD, Li S, et al. Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34328530. doi:10.1007/s00259-021-05489-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。